RU2009139073A - Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-нт6 - Google Patents

Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-нт6 Download PDF

Info

Publication number
RU2009139073A
RU2009139073A RU2009139073/04A RU2009139073A RU2009139073A RU 2009139073 A RU2009139073 A RU 2009139073A RU 2009139073/04 A RU2009139073/04 A RU 2009139073/04A RU 2009139073 A RU2009139073 A RU 2009139073A RU 2009139073 A RU2009139073 A RU 2009139073A
Authority
RU
Russia
Prior art keywords
alkyl
alkoxy
haloalkyl
radical
haloalkoxy
Prior art date
Application number
RU2009139073/04A
Other languages
English (en)
Russian (ru)
Inventor
Шон Кольм ТЕРНЕР (DE)
Шон Кольм ТЕРНЕР
Андреас ХАУПТ (DE)
Андреас ХАУПТ
Вильфрид БРАЙЕ (DE)
Вильфрид БРАЙЕ
Удо ЛАНГЕ (DE)
Удо ЛАНГЕ
Карла ДРЕШЕР (DE)
Карла ДРЕШЕР
Карстен ВИККЕ (DE)
Карстен ВИККЕ
Лилиане УНГЕР (DE)
Лилиане УНГЕР
Марио МЕЦЛЕР (DE)
Марио МЕЦЛЕР
Вольфганг ВЕРНЕТ (DE)
Вольфганг ВЕРНЕТ
Маттиас МАЙРЕР (DE)
Маттиас МАЙРЕР
Original Assignee
Эбботт Гмбх Унд Ко.Кг (De)
Эбботт Гмбх Унд Ко.Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Гмбх Унд Ко.Кг (De), Эбботт Гмбх Унд Ко.Кг filed Critical Эбботт Гмбх Унд Ко.Кг (De)
Publication of RU2009139073A publication Critical patent/RU2009139073A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2009139073/04A 2007-03-23 2008-03-20 Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-нт6 RU2009139073A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104806.0 2007-03-23
EP07104806 2007-03-23

Publications (1)

Publication Number Publication Date
RU2009139073A true RU2009139073A (ru) 2011-04-27

Family

ID=39620293

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009139073/04A RU2009139073A (ru) 2007-03-23 2008-03-20 Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-нт6

Country Status (24)

Country Link
US (1) US8242102B2 (enExample)
EP (1) EP2139880B1 (enExample)
JP (1) JP5538907B2 (enExample)
KR (1) KR20090128426A (enExample)
CN (1) CN101679351B (enExample)
AR (1) AR068381A1 (enExample)
AT (1) ATE524456T1 (enExample)
AU (1) AU2008231787A1 (enExample)
BR (1) BRPI0809081A2 (enExample)
CA (1) CA2681030C (enExample)
CO (1) CO6230989A2 (enExample)
CR (1) CR11039A (enExample)
DO (1) DOP2009000228A (enExample)
EC (1) ECSP099651A (enExample)
ES (1) ES2373617T3 (enExample)
IL (1) IL201105A0 (enExample)
MX (1) MX2009010243A (enExample)
NZ (1) NZ579735A (enExample)
PE (1) PE20091187A1 (enExample)
RU (1) RU2009139073A (enExample)
TW (1) TW200940524A (enExample)
UA (1) UA97837C2 (enExample)
UY (1) UY31326A (enExample)
WO (1) WO2008116831A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140120036A1 (en) * 2012-01-06 2014-05-01 Abbvie Inc. Radiolabeled 5-ht6 ligands
US20130343993A1 (en) * 2012-01-06 2013-12-26 Abbvie Inc. Radiolabeled 5-ht6 ligands
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
US10160744B2 (en) * 2016-03-14 2018-12-25 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法
CN109503449A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 一种3-硝基吖丁啶-1-甲酸叔丁酯的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383759A1 (en) * 1999-09-02 2001-03-15 Wakunaga Pharmaceutical Co., Ltd. Quinolinecarboxylic acid derivative or its salt
JP2003277416A (ja) 2002-03-22 2003-10-02 Daiyanitorikkusu Kk 糖類を含むアクリルアミド水溶液
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
US20050165006A1 (en) 2002-04-03 2005-07-28 Dae-Yoon Chi Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
JP4390698B2 (ja) 2002-06-05 2009-12-24 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置のための5−ht6レセプターモジュレーターとしての1−スルホニル−4−アミノアルコキシインドール誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
BRPI0614483A2 (pt) 2005-07-27 2011-03-29 Hoffmann La Roche ariloxiquinolinas e usos das mesmas como 5-ht6
GB0519765D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
EP2120950B1 (en) 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain

Also Published As

Publication number Publication date
UA97837C2 (ru) 2012-03-26
ECSP099651A (es) 2009-10-30
NZ579735A (en) 2012-02-24
HK1139933A1 (en) 2010-09-30
US20110009380A1 (en) 2011-01-13
JP5538907B2 (ja) 2014-07-02
BRPI0809081A2 (pt) 2019-09-24
CA2681030A1 (en) 2008-10-02
TW200940524A (en) 2009-10-01
JP2010521520A (ja) 2010-06-24
DOP2009000228A (es) 2009-10-15
ATE524456T1 (de) 2011-09-15
CA2681030C (en) 2015-01-13
US8242102B2 (en) 2012-08-14
CO6230989A2 (es) 2010-12-20
CN101679351B (zh) 2015-01-07
PE20091187A1 (es) 2009-09-06
EP2139880B1 (en) 2011-09-14
MX2009010243A (es) 2009-12-14
CR11039A (es) 2010-02-09
WO2008116831A1 (en) 2008-10-02
KR20090128426A (ko) 2009-12-15
AR068381A1 (es) 2009-11-11
CN101679351A (zh) 2010-03-24
EP2139880A1 (en) 2010-01-06
UY31326A (es) 2009-11-10
IL201105A0 (en) 2010-05-17
AU2008231787A1 (en) 2008-10-02
ES2373617T3 (es) 2012-02-07

Similar Documents

Publication Publication Date Title
JP2021534124A5 (enExample)
RU2010108282A (ru) Соединения хинолина, пригодные для лечения нарушений, являющихся ответом на модуляцию рецептора 5-нт6 серотонина
JP2016506960A5 (enExample)
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
JP2018502877A5 (enExample)
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
RU2010150786A (ru) Пирролопиридины как ингибиторы киназы
IL291590B2 (en) Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
RU2017123114A (ru) 3-оксо-3-(ариламино)пропионаты, способ их получения и их применение в получении пирролидинонов
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
JP2014506599A5 (enExample)
RU2006134020A (ru) Конденсированные производные пиразола
JP2017533968A5 (enExample)
RU2009144538A (ru) Новые циклические пептидные соединения
AR058403A1 (es) PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF.
RU2006112593A (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk
JP2015517574A5 (enExample)
JP2013509392A5 (enExample)
JP2016506959A5 (enExample)
RU2011136821A (ru) Дигидрохинолиноновые производные
PE20141000A1 (es) Ureas asimetricas y usos medicos de las mismas
RU2007106180A (ru) Производные индола, индазола или индолина
AR093047A1 (es) Compuestos heterociclicos nitrogenados
AR069691A1 (es) Derivados ciclopropilamina
RU2010150345A (ru) Производные хиназолина

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120808